HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VIGONVITA-B

79.700

-2.700-3.28%

Volume:80.80K

Turnover:6.52M

Market Cap:13.39B

PE:-34.21

High:83.800

Open:82.300

Low:78.650

Close:82.400

52wk High:134.900

52wk Low:51.000

Shares:168.00M

HK Float Shares:167.00M

Volume Ratio:1.01

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.330

ROE:-123.98%

ROA:-20.73%

PB:53.31

PE(LYR):-34.21

PS:52.64

Loading ...

Overview Company News Filings

VIGONVITA-B Receives CSRC Approval for H-Share Full Circulation Plan

Vigonvita Says CSRC Completes Filing for H-share Full Circulation of 100,220,667 Shares

Vigonvita Life Sciences announces postponement of annual general meeting

Vigonvita Life Sciences calls 26 June 2026 AGM; tables board overhaul, RMB50 million subsidiary guarantees and fresh H-share mandates

Bulletin Express

Vigonvita Schedules 26 June 2026 AGM to Decide on Board Overhaul, Supervisory Committee Abolition and Share Issuance Mandates

Bulletin Express

Vigonvita to Replace Deloitte with HLB Hodgson Impey Cheng; Estimated 2026 Audit Fee Set at RMB 2.48 Million

Bulletin Express

VIGONVITA-B Proposes Appointment of New Auditor to Succeed Deloitte

Vigonvita proposes auditor switch to HLB after Deloitte fee talks stall

VIGONVITA-B Maintains Unchanged Share Base and Public-Float Compliance in May 2026 Update

Bulletin Express

Vigonvita Issues Supplemental Results Disclosure After HK$16.00 Million IPO Funds Were Misallocated to Unlisted Fund

Bulletin Express

Vigonvita says it redeems HK$16 million fund stake inadvertently funded with IPO proceeds

Vigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps

Bulletin Express

Vigonvita says auditor flags no issues in continuing connected API purchases

Vigonvita Life Sciences : April 2026 Monthly Return Shows Unchanged Share Base and Full Public Float Compliance

Bulletin Express

Vigonvita Life Sciences publishes 2025 annual report

维昊生物2025年业绩：收入突破1.02096亿元，股权激励及上市费用致年度亏损扩大

Bulletin Express

Vigonvita nominates new board slate as first-term directors near end of mandate

Vigonvita Life Sciences Formalises Corporate Charter, Clarifies Capital Base and Governance Structure

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/02630/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02630\",,,,,undefined,":{"symbol":"02630","market":"HK","secType":"STK","nameCN":"VIGONVITA-B","latestPrice":79.7,"timestamp":1791444758981,"preClose":82.4,"halted":0,"volume":80800,"delay":0,"changeRate":-0.03276699029126217,"floatShares":167000000,"shares":168000000,"eps":-2.33,"marketStatus":"Trading","change":-2.7,"latestTime":"10-08 15:41:00","open":82.3,"high":83.8,"low":78.65,"amount":6517730,"amplitude":0.0625,"askPrice":79.8,"askSize":400,"bidPrice":79.05,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-2.185125,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791447000000},"marketStatusCode":2,"adr":0,"listingDate":1762358400000,"exchange":"SEHK","adjPreClose":82.4,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":1.014019,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02630\",,,,,undefined,":{"symbol":"02630","floatShares":167000000,"roa":"-20.73%","roe":"-123.98%","lyrEps":-2.33,"volumeRatio":1.014019,"shares":168000000,"dividePrice":0,"high":83.8,"amplitude":0.0625,"preClose":82.4,"low":78.65,"week52Low":51,"pbRate":"53.31","psRate":"52.64","week52High":134.9,"institutionHeld":0,"latestPrice":79.7,"eps":-2.33,"divideRate":0,"volume":80800,"delay":0,"ttmEps":-2.185125,"open":82.3,"prevYearClose":81.85,"prevWeekClose":81.2,"prevMonthClose":79,"prevQuarterClose":79,"fiveDayClose":79,"twentyDayClose":81.9,"sixtyDayClose":58.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02630\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-31","symbol":"02630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774920600000,"name":null,"time":"","dateTimestamp":1774886400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02630\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02630","date":"2026-10-07","current":-36.473886,"percent":0.097778,"low":-51.703739,"twenty":-36.095929,"median":-25.195591,"eighty":-19.440166,"high":-9.647367,"avg":-26.654703,"sd":9.26824,"marketCap":13810058720},"quantilePoints":[{"date":"2025-11-07","current":-19.090342,"twenty":-21.84559,"median":-19.090342,"eighty":-13.424557,"marketCap":4407358491},{"date":"2025-11-14","current":-19.641187,"twenty":-19.420849,"median":-16.095168,"eighty":-15.264414,"marketCap":4547380470},{"date":"2025-11-21","current":-17.28769,"twenty":-19.452561,"median":-18.09445,"eighty":-15.501254,"marketCap":4000627980},{"date":"2025-11-28","current":-20.095977,"twenty":-19.591091,"median":-19.037434,"eighty":-16.046947,"marketCap":4667399310},{"date":"2025-12-05","current":-22.096294,"twenty":-21.259546,"median":-19.451229,"eighty":-16.716837,"marketCap":5140806954},{"date":"2025-12-12","current":-20.997063,"twenty":-21.601599,"median":-19.578567,"eighty":-17.610394,"marketCap":4894101562},{"date":"2025-12-19","current":-23.416326,"twenty":-21.853997,"median":-20.095977,"eighty":-18.35497,"marketCap":5470858762},{"date":"2025-12-24","current":-23.9553,"twenty":-22.587001,"median":-20.380599,"eighty":-18.745749,"marketCap":5614214598},{"date":"2026-01-02","current":-23.818881,"twenty":-23.195416,"median":-20.975608,"eighty":-18.936771,"marketCap":5604213028},{"date":"2026-01-09","current":-24.028271,"twenty":-23.242124,"median":-21.499422,"eighty":-19.069179,"marketCap":5667556305},{"date":"2026-01-16","current":-25.359291,"twenty":-23.625318,"median":-21.781264,"eighty":-19.370201,"marketCap":6000941970},{"date":"2026-01-23","current":-26.793845,"twenty":-23.828886,"median":-22.096294,"eighty":-19.449016,"marketCap":6334327635},{"date":"2026-01-30","current":-27.921283,"twenty":-24.928673,"median":-22.61666,"eighty":-19.453005,"marketCap":6631040876},{"date":"2026-02-06","current":-29.544924,"twenty":-25.987891,"median":-22.879289,"eighty":-19.503447,"marketCap":7034437531},{"date":"2026-02-13","current":-30.629205,"twenty":-27.286118,"median":-23.1966,"eighty":-19.616139,"marketCap":7334484630},{"date":"2026-02-20","current":-34.884005,"twenty":-27.587073,"median":-23.306067,"eighty":-19.674728,"marketCap":8341309338},{"date":"2026-02-27","current":-31.168111,"twenty":-28.783656,"median":-23.424434,"eighty":-19.866309,"marketCap":7534516029},{"date":"2026-03-06","current":-27.5285,"twenty":-28.691787,"median":-23.667752,"eighty":-20.125096,"marketCap":6601036167},{"date":"2026-03-13","current":-30.889856,"twenty":-29.277344,"median":-23.818881,"eighty":-20.297184,"marketCap":7441168042},{"date":"2026-03-20","current":-35.008205,"twenty":-30.149829,"median":-23.991785,"eighty":-20.606532,"marketCap":8401318758},{"date":"2026-03-27","current":-24.261842,"twenty":-30.04822,"median":-24.440897,"eighty":-20.962736,"marketCap":5807578284},{"date":"2026-04-02","current":-13.839173,"twenty":-29.95186,"median":-24.028271,"eighty":-20.954154,"marketCap":5600879172},{"date":"2026-04-10","current":-14.403566,"twenty":-29.707698,"median":-23.912102,"eighty":-20.183335,"marketCap":5874255417},{"date":"2026-04-17","current":-13.931767,"twenty":-29.472848,"median":-23.687448,"eighty":-19.490947,"marketCap":5684225588},{"date":"2026-04-24","current":-13.154764,"twenty":-29.345649,"median":-23.63573,"eighty":-19.048016,"marketCap":5367509206},{"date":"2026-04-30","current":-11.730061,"twenty":-29.261806,"median":-23.42038,"eighty":-17.610394,"marketCap":4787418149},{"date":"2026-05-08","current":-12.584922,"twenty":-29.118763,"median":-23.285925,"eighty":-15.264414,"marketCap":5154142380},{"date":"2026-05-15","current":-12.982213,"twenty":-28.928188,"median":-23.15168,"eighty":-14.197911,"marketCap":5330836783},{"date":"2026-05-22","current":-13.28049,"twenty":-28.680958,"median":-22.671486,"eighty":-13.975486,"marketCap":5440854052},{"date":"2026-05-29","current":-30.758632,"twenty":-28.951155,"median":-22.671486,"eighty":-13.922465,"marketCap":12645254010},{"date":"2026-06-05","current":-26.663627,"twenty":-28.786309,"median":-23.15168,"eighty":-13.953626,"marketCap":10977655900},{"date":"2026-06-12","current":-24.767111,"twenty":-28.478214,"median":-23.285925,"eighty":-14.04116,"marketCap":10189946240},{"date":"2026-06-18","current":-23.79348,"twenty":-28.413466,"median":-23.416326,"eighty":-14.041546,"marketCap":9812851190},{"date":"2026-06-26","current":-24.094013,"twenty":-28.02179,"median":-23.475951,"eighty":-14.17377,"marketCap":9888270200},{"date":"2026-07-03","current":-23.973985,"twenty":-27.941384,"median":-23.572922,"eighty":-14.1825,"marketCap":9846370750},{"date":"2026-07-10","current":-22.062739,"twenty":-27.729315,"median":-23.424434,"eighty":-14.21114,"marketCap":9050281200},{"date":"2026-07-17","current":-23.043014,"twenty":-27.655709,"median":-23.42038,"eighty":-14.359864,"marketCap":9486035480},{"date":"2026-07-24","current":-31.748257,"twenty":-27.941384,"median":-23.52511,"eighty":-14.401931,"marketCap":13072628400},{"date":"2026-07-31","current":-38.65537,"twenty":-28.640355,"median":-23.612983,"eighty":-14.919422,"marketCap":15946930670},{"date":"2026-08-07","current":-47.358881,"twenty":-29.345649,"median":-23.667752,"eighty":-15.264958,"marketCap":19575423040},{"date":"2026-08-14","current":-37.215568,"twenty":-30.11107,"median":-23.79348,"eighty":-15.618859,"marketCap":15402237820},{"date":"2026-08-21","current":-35.214198,"twenty":-30.680976,"median":-23.843893,"eighty":-16.143388,"marketCap":14606148270},{"date":"2026-08-28","current":-40.255874,"twenty":-31.400169,"median":-23.9553,"eighty":-16.907121,"marketCap":16701120770},{"date":"2026-09-04","current":-44.821322,"twenty":-32.610186,"median":-24.007881,"eighty":-17.771746,"marketCap":15938550780},{"date":"2026-09-11","current":-35.300408,"twenty":-33.782678,"median":-24.094013,"eighty":-18.485229,"marketCap":12569835000},{"date":"2026-09-18","current":-39.484866,"twenty":-34.88923,"median":-24.35137,"eighty":-18.889015,"marketCap":14078215200},{"date":"2026-09-25","current":-39.607357,"twenty":-35.248682,"median":-24.767111,"eighty":-19.048016,"marketCap":14094974980},{"date":"2026-10-02","current":-38.201311,"twenty":-35.678655,"median":-24.951059,"eighty":-19.230272,"marketCap":13608941360},{"date":"2026-10-07","current":-38.710585,"twenty":-36.095929,"median":-25.195591,"eighty":-19.440166,"marketCap":13810058720}],"updateTime":1791445260387},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02630\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152157189","title":"VIGONVITA-B Receives CSRC Approval for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1152157189","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152157189?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:50","pubTimestamp":1782726619,"startTime":"0","endTime":"0","summary":"The China Securities Regulatory Commission has issued a filing notice to VIGONVITA-B (02630) regarding the implementation of its H-share full circulation plan.According to the notice, the filing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647676320","title":"Vigonvita Says CSRC Completes Filing for H-share Full Circulation of 100,220,667 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2647676320","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647676320?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:45","pubTimestamp":1782726343,"startTime":"0","endTime":"0","summary":"Vigonvita says CSRC completes filing for H-share full circulation of 100,220,667 sharesVigonvita received a China securities regulator filing notice for its H-share full circulation plan.The filing co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9hgLl0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643249729","title":"Vigonvita Life Sciences announces postponement of annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643249729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643249729?lang=en_us&edition=fundamental","pubTime":"2026-06-14 19:45","pubTimestamp":1781437556,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences will hold its postponed annual general meeting in Suzhou, China on June 30, 2026.The meeting was rescheduled from June 26 due to internal work-schedule adjustments.Shareholders will vote on the resolutions set out in the June 4 AGM notice and the June 14 supplemental notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDL8nM9B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180313934","title":"Vigonvita Life Sciences calls 26 June 2026 AGM; tables board overhaul, RMB50 million subsidiary guarantees and fresh H-share mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1180313934","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180313934?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:03","pubTimestamp":1780585420,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences (Vigonvita) has issued a circular convening its 2026 annual general meeting (AGM) for 26 June 2026 in Suzhou. Fifteen resolutions will be put to vote, spanning financial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116682637","title":"Vigonvita Schedules 26 June 2026 AGM to Decide on Board Overhaul, Supervisory Committee Abolition and Share Issuance Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1116682637","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116682637?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:02","pubTimestamp":1780585375,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. will convene its 2026 annual general meeting (AGM) at 10:00 a.m. on 26 June 2026 at the group’s Suzhou headquarters (8th Floor, Building A, No. 108 Yuxin Road,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198311803","title":"Vigonvita to Replace Deloitte with HLB Hodgson Impey Cheng; Estimated 2026 Audit Fee Set at RMB 2.48 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1198311803","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198311803?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:23","pubTimestamp":1780582990,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. announced that incumbent auditor Deloitte Touche Tohmatsu will retire at the end of the 26 June 2026 annual general meeting after the two parties failed to agree on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150892644","title":"VIGONVITA-B Proposes Appointment of New Auditor to Succeed Deloitte","url":"https://stock-news.laohu8.com/highlight/detail?id=1150892644","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150892644?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:20","pubTimestamp":1780582817,"startTime":"0","endTime":"0","summary":"VIGONVITA-B has announced that its current auditor, Deloitte Touche Tohmatsu, will retire upon the conclusion of the company's upcoming annual general meeting, scheduled for June 26, 2026, and will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640163613","title":"Vigonvita proposes auditor switch to HLB after Deloitte fee talks stall","url":"https://stock-news.laohu8.com/highlight/detail?id=2640163613","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640163613?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:05","pubTimestamp":1780581955,"startTime":"0","endTime":"0","summary":"Vigonvita plans to replace auditor Deloitte with HLB Hodgson Impey Cheng from the June 26, 2026 AGM.Deloitte will retire at the AGM and will not seek reappointment following a fee dispute for the 2026 audit.HLB’s estimated audit fee for the year ending Dec. 31, 2026 is RMB 2.48 million.Deloitte reported no issues requiring shareholder attention; no other disputes cited beyond audit fees.Board expects no impact on the 2026 annual audit timetable or results publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 04, 2026, and is solely responsibl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL1ZbjPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152862710","title":"VIGONVITA-B Maintains Unchanged Share Base and Public-Float Compliance in May 2026 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1152862710","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152862710?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:25","pubTimestamp":1780565109,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B) has filed its Monthly Return on Movements in Securities for the period ended 31 May 2026 with Hong Kong Exchanges and Clearing Limited, confirming a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190760798","title":"Vigonvita Issues Supplemental Results Disclosure After HK$16.00 Million IPO Funds Were Misallocated to Unlisted Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=1190760798","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190760798?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:03","pubTimestamp":1780318991,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (Vigonvita) released a supplemental announcement to its 2025 annual results, clarifying the unintended use of HK$16.00 million (approximately RMB14.42 million) in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954652","title":"Vigonvita says it redeems HK$16 million fund stake inadvertently funded with IPO proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954652","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954652?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:56","pubTimestamp":1780318597,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences clarified that HKD 16 million of IPO proceeds was inadvertently used in January 2026 to subscribe an unlisted market fund.The subscription was redeemed once identified, with the board attributing the breach to a finance oversight rather than intentional misuse.New controls include transaction approvals for deals of RMB 2 million or more to verify funding sources, with added training on disclosure rules.It reaffirmed IPO proceeds will be used as set out in the prospectus, noting the transactions stayed below 5% size-test thresholds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure syst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL3vlq8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148332748","title":"Vigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps","url":"https://stock-news.laohu8.com/highlight/detail?id=1148332748","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148332748?lang=en_us&edition=fundamental","pubTime":"2026-05-25 18:23","pubTimestamp":1779704590,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534136","title":"Vigonvita says auditor flags no issues in continuing connected API purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638534136?lang=en_us&edition=fundamental","pubTime":"2026-05-25 18:17","pubTimestamp":1779704276,"startTime":"0","endTime":"0","summary":"Vigonvita issued a supplemental statement to its 2025 annual report after receiving an independent auditor letter dated May 22, 2026.Deloitte Touche Tohmatsu reported no issues found with disclosed continuing connected transactions for API purchases and ancillary services.The auditor said nothing indicated the transactions lacked board authorization, breached agreement terms, or exceeded the annual caps disclosed in the prospectus.The board said none of the transactions involved the group providing goods or services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exch","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nNDLtpCTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165772726","title":"Vigonvita Life Sciences : April 2026 Monthly Return Shows Unchanged Share Base and Full Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1165772726","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165772726?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:43","pubTimestamp":1778107399,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. submitted its monthly return for the period ended 30 April 2026, confirming a stable capital structure and adherence to Hong Kong Listing Rule public-float...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631962632","title":"Vigonvita Life Sciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631962632","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631962632?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:28","pubTimestamp":1777552139,"startTime":"0","endTime":"0","summary":"Vigonvita reported in its annual report for year ended Dec. 31, 2025 that commercialization of erectile dysfunction drug Angweida  began in 2025, with first batch delivered in early August following marketing clearance on July 8.License-out program for VV116 in respiratory syncytial virus supported revenue growth via milestone receipts, with VV116 dry suspension completing Phase II in 2025 then moving into Phase III following an End-of-Phase 2 meeting in December.Simcere Pharmaceutical deal signed in December grants exclusive Greater China rights for VV116 in RSV infection, human metapneumovirus infection, with Vigonvita eligible for upfront payment, milestones, royalties.Digital-first go-to-market expanded, with a 22-person digital marketing team formed, flagship stores opened across six major China platforms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL7zC0xF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146130353","title":"维昊生物2025年业绩：收入突破1.02096亿元，股权激励及上市费用致年度亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1146130353","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146130353?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:27","pubTimestamp":1777552072,"startTime":"0","endTime":"0","summary":"维昊生物科技有限公司（Vigonvita-B）近日发布截至2025年12月31日止年度业绩，显示主营业务快速增长的同时，整体亏损扩大。公司于2025年11月6日正式在香港联交所主板挂牌上市，募集总款项约为5.87亿港元。 ■ 业绩与财务表现...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"维昊生物2025年业绩：收入突破1.02096亿元，股权激励及上市费用致年度亏损扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631863291","title":"Vigonvita nominates new board slate as first-term directors near end of mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2631863291","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631863291?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:27","pubTimestamp":1777552066,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences flagged a board refresh ahead of expiry of first board term on March 26, 2026.Chairman and CEO Tian Guanghui was nominated to continue as executive director; he joined Vigonvita in 2013 and previously worked at API-focused drug developer Topharman Shanghai.Deputy general manager Hu Tianwen was nominated to continue as executive director; he previously served as a researcher at Topharman Shanghai from 2016 to 2022.Non-executive director Liu Haoxuan was nominated to continue; he is general manager of Yunnan Suwangrun Biopharmaceutical since 2021.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1JTtBg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174778936","title":"Vigonvita Life Sciences Formalises Corporate Charter, Clarifies Capital Base and Governance Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=1174778936","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174778936?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:43","pubTimestamp":1776944588,"startTime":"0","endTime":"0","summary":"Vigonvita Life Sciences Co., Ltd. has released its revised Articles of Association, detailing the company’s post-IPO share capital, equity structure, and corporate governance framework. Capital &...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}